VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AARD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AARDAardvark Therapeutics, Inc. Common Stock
$1.17$26M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
AARD logo

Aardvark Therapeutics, Inc. Common Stock

AARD
NASDAQ · Rare Disease Biotech
$1.17
At close - Nov 6, 4:00 PM EST - USD
Market Cap$26M
P/E-0.4x
52W High$16.60
Volume221.71K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Accelerating Clinical Spend Pressures Capital Runway

Aardvark Therapeutics is currently in a high-stakes transition toward Phase III clinical execution, characterized by a rapid escalation in R&D spending that has reached $16.6 million per quarter as of 2026Q1.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

AARD price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

3/12 Beats

EPS beat 3 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 2 · Lag

Laggard (Underperforming 98% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystConfirmed earnings · Nov 12

Market performance

Price History →

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
AARD-91.13%
S&P 500 (^GSPC)+7.63%
1-Year Return
AARD-88.15%
S&P 500 (^GSPC)+9.69%
3-Year Return
AARD-91.82%
S&P 500 (^GSPC)+72.00%
5-Year Return
AARD-91.82%
S&P 500 (^GSPC)+61.40%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$58M-179.7% YoY
Free cash flow FY25
-$54M-198.2% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-
ROE (TTM)-71.5%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate3/12 (38%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 11, 2026
-$0.66+24.5%
vs -$0.87
—
vs —
Q2 2026
May 7, 2026
-$0.99-12.9%
vs -$0.88
—
vs —
Q2 2026
Mar 23, 2026
-$0.81+2.1%
vs -$0.83
—
vs —
Q4 2025
Nov 13, 2025
-$0.75+6.1%
vs -$0.80
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Oct 23, 2026
Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Benzinga·Oct 23, 2026
Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient

Aardvark Therapeutics Inc. (NASDAQ:AARD) stock plunged on Friday after the release of exploratory efficacy data from its terminated Phase 3 HERO trial and open-label extension study.

GlobeNewsWire·Oct 23, 2026
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.

GlobeNewsWire·Oct 22, 2026
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data

Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's Investigational New Drug application for ARD-101 for the treatment of hyperphagia in PWS.

Filtered for Aardvark Therapeutics, Inc. Common StockMore Headlines
04

Compare before deciding

Benchmark AARD against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Aardvark Therapeutics, Inc. Common Stock (AARD)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
AARD logoAARDAardvark Therapeutics, Inc. Common StockCurrent
$1.17$25.6M-0.37——-71.54%—
RYTM logoRYTMRhythm Pharmaceuticals, Inc.
$112.28$7.7B-40.0045.83%-69.03%-83.68%—
VNDA logoVNDAVanda Pharmaceuticals Inc.
$3.82$229.72M-0.848.72%-119.87%-106.94%—
IMVT logoIMVTImmunovant, Inc.
$30.53$6.3B-11.66—-7585.86%-69.59%—
CGEM logoCGEMCullinan Therapeutics, Inc.
$11.31$695.09M-3.40——-52.89%—
VKTX logoVKTXViking Therapeutics, Inc.
$26.84$3.13B-5.05——-117.35%—

Compare AARD vs Peers

Aardvark Therapeutics, Inc. Common Stock (AARD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RYTM

Most directly comparable listed peer for AARD.

Scale Benchmark

vs LLY

Larger-name benchmark to compare AARD against a more recognizable public peer.

Peer Set

Compare Top 5

vs RYTM, VNDA, IMVT, CGEM

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

AARD SEC Filings & Documents

Aardvark Therapeutics, Inc. Common Stock (AARD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 17, 2026·SEC

Material company update

Aug 11, 2026·SEC

Material company update

Jun 12, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

5
FY 2026

Aug 11, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when AARD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

AARD Frequently Asked Questions

Aardvark Therapeutics, Inc. Common Stock (AARD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is AARD profitable?

No. Aardvark Therapeutics, Inc. Common Stock (AARD) reported a net loss of $69.9M over the trailing twelve months.

Dividend & Returns
What is AARD's return on equity?

Aardvark Therapeutics, Inc. Common Stock (AARD) had a return on equity (ROE) of -71.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Aardvark Therapeutics, Inc. Common Stock's free cash flow?

Aardvark Therapeutics, Inc. Common Stock (AARD) had negative free cash flow of $69.4M over the trailing twelve months.

What if you invested $1,000 in AARD back in 2022?

Total return calculator · dividends reinvested · 4+ years of data

See returns →